Abstract
Gene therapy is based on the genome modifications by introducing nucleic acids in the cells of the patient to treat diseases. There are different gene therapy strategies, the most common of which is to add a healthy copy of the disease-inducing gene. Other strategies consist of replacing the gene which is responsible for the disease for a healthy copy, or to inactivate a gene that is functioning improperly. Gene therapy is designed for untreatable diseases or with a heavy treatment.
To modify the genome of patients, different gene vectors are used. There are two major classes of them, synthetic vectors which are complexes between nucleic acids (DNA, RNA, or protein) and synthetic molecules and viral vectors which are derived from viruses. Each of them has their advantages and limits.
The vectors can be administered directly in vivo or used for ex vivo approaches which consist to genetically modify the patient cells in vitro before being reintroduced into the patient.
This chapter gives a statement of the art of gene therapy. It describes the different strategies and tools used in this area before describing the seminal clinical trials and the range of diseases for which gene therapy could be relevant. This chapter concludes by considering the issues and challenges of the gene therapy.
References
Ahmed SG, Waddington SN, Boza-Morán MG, Yáñez-Muñoz RJ (2018) High-efficiency transduction of spinal cord motor neurons by intrauterine delivery of integration-deficient lentiviral vectors. J Control Release 273:99–107
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F et al (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410–2413
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447
Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC et al (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:1233151
Alonso-Padilla J, Papp T, Kaján GL, Benkő M, Havenga M, Lemckert A, Harrach B, Baker AH (2016) Development of novel adenoviral vectors to overcome challenges observed with HAdV-5–based constructs. Mol Ther 24:6–16
Benchaouir R, Meregalli M, Farini A, D’Antona G, Belicchi M, Goyenvalle A, Battistelli M, Bresolin N, Bottinelli R, Garcia L et al (2007) Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1:646–657
Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P et al (1995) T lymphocyte-directed gene therapy for ADA−SCID: initial trial results after 4 years. Science 270:475–480
Boado RJ, Zhang Y, Zhang Y, Xia C-F, Pardridge WM (2007) Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 18:447–455
Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U (2009) Breaking the code of DNA binding sof TAL-type III effectors. Science 326:1509–1512
Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18:498
Campeau P, Chapdelaine P, Seigneurin-Venin S, Massie B, Tremblay JP (2001) Transfection of large plasmids in primary human myoblasts. Gene Ther 8:1387–1394
Cavalieri V, Baiamonte E, Lo Iacono M (2018) Non-primate lentiviral vectors and their applications in gene therapy for ocular disorders. Viruses 10:316
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823
Curran KJ, Pegram HJ, Brentjens RJ (2012) Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 14:405–415
Darrow JJ (2019) Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today 24:949
Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DWY (2018) Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 17:641–659
Ding S, Wu X, Li G, Han M, Zhuang Y, and Xu T (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122 473–483
Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS (2007) AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477–477
Duncan C, Eichler F, Thrasher AJ, Orchard PJ, De Oliveira SN, Lund TC, Amartino H, Smith NJC, McNeil E, Chin W et al (2019) Updated safety and efficacy outcomes from an ongoing phase 2/3 trial of lenti-D autologous hematopoietic stem cell gene therapy for the treatment of cerebral adrenoleukodystrophy. Biol Blood Marrow Transplant 25:S89–S90
Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84:7413–7417
Fisher J, Anderson J (2018) Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front Immunol 9:1409
Friedmann T, Roblin R (1972) Gene therapy for human genetic disease? Science 175:949–955
Gounis MJ, Spiga M-G, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, Webster KA (2005) Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 12:762–771
Gray SJ, Woodard KT, Samulski RJ (2010) Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv 1:517–534
Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179–1188
Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR et al (2016) Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet Lond Engl 387:1178–1186
Guo J, Xin H (2006) Splicing out the west? Science 314:1232–1235
Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H et al (2019) HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 568:244–248
Hacein-Bey-Abina S, Kalle CV, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419
Hess B, Saftig P, Hartmann D, Coenen R, Lüllmann-Rauch R, Goebel HH, Evers M, von Figura K, D’Hooge R, Nagels G et al (1996) Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci U S A 93:14821–14826
Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M et al (2018) A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 18:596
Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D et al (2017) Regeneration of the entire human epidermis using transgenic stem cells. Nature 551:327–332
Hu Y, Tian Z, Zhang C (2018) Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin 39:167–176
Ivics Z, Hackett PB, Plasterk RH, and Izsvák Z (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91 501–510
Jordan Calmes-Miller (2016) Railroading at the FDA. Nat Biotechnol 34:1078
Jordan Calmes-Miller (2018) FDA approves second CAR T-cell therapy. Cancer Discov 8:5–6
Khorkova O, Wahlestedt C (2017) Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol 35:249–263
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918–928
Kohn DB (2019) Gene therapy for blood diseases. Curr Opin Biotechnol 60:39–45
Krimsky S (2019) Ten ways in which He Jiankui violated ethics. Nat Biotechnol 37:19–20
Li T, Adamian M, Roof DJ, Berson EL, Dryja TP, Roessler BJ, Davidson BL (1994) In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci 35:2543–2549
Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue S, Fletcher S, Partridge TA, Wilton SD (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9:1009–1014
Maetzig T, Galla M, Baum C, Schambach A (2011) Gammaretroviral vectors: biology, technology and application. Viruses 3:677–713
Magee TR, Artaza JN, Ferrini MG, Vernet D, Zuniga FI, Cantini L, Reisz-Porszasz S, Rajfer J, Gonzalez-Cadavid NF (2006) Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J. Gene Med. 8:1171–1181
Matzner U, Hartmann D, Lüllmann-Rauch R, Coenen R, Rothert F, Månsson J-E, Fredman P, D’Hooge R, De Deyn PP, Gieselmann V (2002) Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther 9:53–63
Moroni MC, Willingham MC, Beguinot L (1992) EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem 267:2714–2722
Monfardini C, Veronese FM (1998) Stabilization of substances in circulation. Bioconjug. Chem. 9 418–450
Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267
Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME, Cara A (2007) Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15:1716–1723
Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E (1999) PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6 595–605
Pardridge WM (2005) Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy. NeuroRx 2:129–138
Pattanayak V, Ramirez CL, Joung JK, Liu DR (2011) Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8:765–770
Perrin GQ, Herzog RW, Markusic DM (2019) Update on clinical gene therapy for hemophilia. Blood 133:407–414
Perumbeti A, Malik P (2010) Therapy for β-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci 1202:36–44
Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, Mallet J, Serguera C (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A 103:17684–17689
Plank C, Mechtler K, Szoka FC, Wagner E (1996) Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. 7 1437–1446
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K et al. (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9
Ribas A, Dummer R, Puzanov I, Vander Walde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170:1109–1119.e10
Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK et al (1998) Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p 53 gene replacement. Semin Oncol 25:33–37
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I et al (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24:1499
Sahel JA, Dalkara D (2019) Gene therapy for retinal dystrophy. Nat Med 25:198
Sarkis C, Altemir D, Grandchamp N, Philippe S (2014) Transient expression vectors, preparation and uses thereof. France
Science AA for the A. of (2000) Biomedical ethics on the front burner. Science 290:2225–2225
Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A et al (2016) Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 388:476–487
Sevin C, Benraiss A, Van Dam D, Bonnin D, Nagels G, Verot L, Laurendeau I, Vidaud M, Gieselmann V, Vanier M et al (2006) Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum Mol Genet 15:53–64
Sheridan C (2017) First approval in sight for Novartis’ CAR-T therapy after panel vote. Nat Biotechnol 35:691–693
Stirnadel-Farrant H, Kudari M, Garman N, Imrie J, Chopra B, Giannelli S, Gabaldo M, Corti A, Zancan S, Aiuti A et al (2018) Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID. Orphanet J Rare Dis 13:49
Tardieu M, Zérah M, Gougeon M-L, Ausseil J, de Bournonville S, Husson B, Zafeiriou D, Parenti G, Bourget P, Poirier B et al (2017) Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol 16:712–720
Tatsis N, Ertl HCJ (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629
Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil J-A, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M et al (2018) Gene therapy in patients with transfusion-dependent β-Thalassemia. N Engl J Med 378:1479
Urnov FD, Miller JC, Lee Y-L, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646–651
Wang X, Wang Y, Wu X, Wang J, Wang Y, Qiu Z, Chang T, Huang H, Lin R-J, Yee J-K (2015) Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33:175–178
Wang C, Zhai X, Zhang X, Li L, Wang J, Liu D (2019a) Gene-edited babies: Chinese Academy of Medical Sciences’ response and action. Lancet 393:25–26
Wang D, Tai PWL, Gao G (2019b) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18:358–378
Williams DS, Chadha A, Hazim R, Gibbs D (2017) Gene therapy approaches for prevention of retinal degeneration in Usher syndrome. Gene Ther 24:68–71
Wilson JM (2005) Gendicine: the first commercial gene therapy product. Hum Gene Ther 16:1014–1015
Xiao X, Li J, Samulski RJ (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098–8108
Xu Y, Szoka FC (1996) Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (Mosc.) 35 5616–5623
Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE et al (2006) Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12:348–353
Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM (2003) Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis 9:465–472
Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B (2005) Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperth 21:631–636
Zhou M, Greenhill S, Huang S, Silva TK, Sano Y, Wu S, Cai Y, Nagaoka Y, Sehgal M, Cai DJ et al (2016) CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory. elife 5:e20985
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Grandchamp, N. (2019). Pharmacodynamic Evaluation: Gene Therapy. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_51-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56637-5_51-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56637-5
Online ISBN: 978-3-319-56637-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences